Short Summary
The petitioner challenged the refusal of his patent application, titled "TAMPER EVIDENT TWIST SEAL WITH BREAKAWAY ANCHOR MECHANISM," which was rejected on grounds of lack of inventive steps/obviousness under Section 25(1)(e) of the Patents Act. The High Court found that the Controller failed to conduct a proper analysis regarding obviousness, specifically failing to consider the differences between the claimed invention and prior art as pointed out by the applicant.
Detailed Summary
In the world of patents, the word "obvious" gets thrown around a lot. But calling an invention obvious without actually proving it? That's not just lazy reasoning — it can be a fatal flaw that unravels an entire rejection. For one inventor with a tamper-evident security seal, a vague obviousness finding became the very reason he won his case against the patent authority.
Mohun Nicholas Dsouza, an independent inventor, filed a patent application titled "TAMPER EVIDENT TWIST SEAL WITH BREAKAWAY ANCHOR MECHANISM" — a specialized security device designed to reveal tampering through a unique mechanical design. The Patent Controller, however, refused to grant the patent, citing Section 25(1)(e) of the Patents Act. The ground? The invention allegedly lacked an inventive step, meaning it was considered "obvious" to a person skilled in the art given what already existed. Dsouza, convinced his invention brought something genuinely new to the table, challenged this refusal before the High Court.
Dsouza's core argument was straightforward but powerful: the Controller had rubber-stamped the rejection without doing the hard analytical work. He pointed out specific differences between his claimed invention and the prior art cited against him — differences that, if properly considered, would have shown his mechanism was not a mere variation of existing designs. On the other side, the Controller stood by the rejection, presumably arguing that the elements of the invention were already known and could be combined without any inventive leap. The legal friction centered on a critical question: did the Controller actually engage with the technical distinctions Dsouza raised, or did it simply declare the invention obvious without substantiating that conclusion?
The High Court sided with Dsouza. The court found that the Controller had failed to conduct a proper analysis of obviousness — specifically, the Controller neglected to consider the differences between the claimed invention and the prior art that the applicant had pointed out. This was not a minor procedural oversight; it struck at the heart of how an obviousness rejection must be reasoned. Drawing on established precedent, including the principles from F. Hoffmann-La Roche Ltd., the court reinforced that rejecting a patent for lack of inventive step requires a detailed, substantive discussion of how a person skilled in the art would move from existing knowledge to the subject invention. Without that analysis, the rejection could not stand. The outcome was favorable to the petitioner.
For founders, inventors, and IP professionals, this case delivers a sharp reminder: an obviousness rejection is not a conclusion — it's an argument that must be built. If you receive a rejection under Section 25(1)(e), scrutinize whether the patent office actually walked through the reasoning required by precedent. Did they identify the person skilled in the art? Did they map the prior art against your claims? Did they address the technical distinctions you raised? If the answer is no, that rejection may be vulnerable. Equally, when drafting or prosecuting a patent application, anticipate the obviousness challenge head-on by clearly articulating what makes your invention non-obvious — the specific technical effect, the unexpected result, or the combination that a skilled person would not naturally arrive at. In patent law, the difference between a granted patent and a refused one often comes down to whether someone did the thinking out loud.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Bombay High Court. Understanding the court's reasoning in Mohun Nicholas D'Souza vs The Controller of Patents of Designs is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Syngenta Participations AgvsController Of Patents And Designs
Syngenta appealed the rejection of its patent application (No. 872/DELNP/2011) for 'Crop Safeners' by the Deputy Controller of Patents & Designs. The primary objection was the lack of specification regarding the ratio of constituents and novelty issues. The High Court found that the suggested amendments could address the non-specification issue and remanded the application for a fresh hearing.
Topotarget Uk LimitedvsThe Controller General Of Patent And Designs, Mumbai and Ors.
Topotarget UK Limited appealed a rejection order against its patent application for a pharmaceutical composition (PXD101 with an in situ salt former). The rejection was based on insufficiency of disclosure, lack of inventive step, and Section 3(d) objections. The High Court found that the Controller misconstrued the invention as a salt per se, failing to consider the multi-component nature of the composition.
M/s. Shilpa Medicare LimitedvsM/s. Salus Pharmaceutical & anr.
M/s. Shilpa Medicare Limited filed a commercial appeal against an order, seeking condonation of delay due to initial incorrect nomenclature. The court allowed the delay condonation, noting that procedural rules are handmaids of justice. Subsequently, the court set aside a single judge's order and remanded the matter for consideration on merits, emphasizing continuous infringement.
Natco Pharma LtdvsBristol Myers Squibb Holdings Ireland Unlimited Company
Natco Pharma Ltd challenged an interim injunction restraining it from infringing Indian Patent IN No.247381, which was held by Bristol Myers Squibb Holdings Ireland and its subsidiaries. The appeal focused on whether the Single Judge had properly considered the merits of the case before issuing a restrictive order. The Delhi High Court ultimately set aside the impugned interim injunction, directing that the application for interim relief be heard again on merits.
Pfizer Products IncvsD Rawal
The contempt petition was filed by Pfizer Products Inc alleging non-compliance with a previous court order. The respondent submitted an affidavit stating that they had applied to the DCGI for permission to manufacture and market the new drug, Tofacitinib, under New Drugs and Clinical Trial Rules, 2019. They undertook not to commercialize the product until the patent expiry date.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.